Get Your Health Score
Echocardiography In The Assessment Of Pediatric Cardiomyopathy
Published on: November 21, 2025
Echocardiography In The Assessment Of Pediatric Cardiomyopathy

Introduction

A healthy heart is vital for children’s growth and development, yet when the heart muscle is affected by cardiomyopathy its ability to pump or fill properly can be impaired. Pediatric cardiomyopathies are uncommon, with an estimated incidence of about 1 per 100,000 children per year.12 Despite their rarity, they are among the most important non-congenital causes of heart failure in children and carry some of the most serious prognoses in paediatric cardiology.3

These conditions are also a recognised, though relatively rare, cause of sudden cardiac arrest in young people, particularly in hypertrophic and arrhythmogenic forms.4,5 The absolute risk varies widely depending on genetic background, disease severity, and clinical features. Prognosis also differs by subtype: registry data suggest that in pediatric dilated cardiomyopathy, up to 40% of children may die or require a heart transplant within two years of diagnosis, whereas five-year transplant-free survival often falls in the 54–65% range.6,7,8 Restrictive cardiomyopathy typically carries a poorer outlook, while some children with milder forms may live longer with careful follow-up and treatment.9

Echocardiography, a safe and repeatable ultrasound test, remains the cornerstone of assessment. It provides real-time information on heart structure, function, and blood flow, and guides both diagnosis and ongoing management. Other tools, such as cardiac MRI and genetic testing, can add further insights, but echocardiography is usually the first and most essential step.10

Understanding pediatric cardiomyopathy

Pediatric cardiomyopathy is a heterogeneous group of disorders that affect the heart muscle’s structure and function. In children, these may be primary (idiopathic or genetic) or arise from secondary causes, including metabolic, mitochondrial, syndromic, neuromuscular, or inflammatory conditions.11, 12

The major phenotypes are dilated cardiomyopathy (DCM), typically the most common in childhood, where the ventricles enlarge and contract poorly;13 hypertrophic cardiomyopathy (HCM), characterised by thickened ventricular walls that may or may not obstruct outflow and which carries a recognised risk of sudden cardiac arrest in some young patients;14, 15 and restrictive cardiomyopathy (RCM), the rarest form, defined by stiff ventricles and impaired filling, often associated with a poorer prognosis.16 Other categories, such as left ventricular non-compaction (LVNC) or arrhythmogenic cardiomyopathy, are sometimes included in classification systems.17

Early identification is critical because outcomes vary widely by subtype, and timely diagnosis can guide monitoring, risk stratification, and family screening. Still, many cases remain genetically unexplained, and the course can be unpredictable.18 Children may present with breathlessness, fatigue, palpitations, chest pain, or fainting; infants may show feeding difficulties, poor growth, or excessive sweating.19 Since these features often mimic more common childhood illnesses, echocardiography is usually the first and most reliable step toward diagnosis and ongoing evaluation.11

Basics of echocardiography

Echocardiography, often called an “echo,” is the first-line imaging test for children with suspected heart muscle disease. It uses ultrasound waves to create moving images of the heart, providing real-time information about its structure and function. Because it is non-invasive, painless, and does not involve radiation, echocardiography is especially well-suited to children, who often need repeated follow-up scans as they grow.

The most widely used method is transthoracic echocardiography (TTE), in which a probe placed on the chest captures images of the chambers, valves, and great vessels. Doppler echocardiography adds flow information: by measuring blood velocity, it can estimate pressure differences and reveal valve leaks, blockages, or abnormal shunts. In specialist centres, more advanced tools are also used. Strain imaging quantifies subtle deformation of the heart muscle, helping to detect early dysfunction before it is visible on standard measures.20,21 Three-dimensional echocardiography (3DE) creates volumetric images, offering a more realistic view of heart anatomy and aiding in complex cases.22

While techniques like cardiac MRI may complement echocardiography for detailed tissue characterisation or when image quality is limited, echocardiography remains the cornerstone of initial and ongoing assessment in paediatric cardiomyopathy.23,24

Echocardiographic assessment in pediatric cardiomyopathy

A comprehensive pediatric echocardiogram typically evaluates four domains: structure, function, blood flow, and how the heart muscle stretches and contracts (known as deformation or “strain”).25 This framework ensures that key aspects of cardiomyopathy are assessed systematically.

Structural assessment involves measuring chamber dimensions, wall thickness, and overall geometry. Dilated cardiomyopathy typically presents with enlarged, thin-walled ventricles, while hypertrophic cardiomyopathy shows disproportionate wall thickening and smaller cavity size.26, 27 Restrictive cardiomyopathy is often characterised by normal-sized ventricles but enlarged atria, and left ventricular noncompaction shows a distinctive “spongy” myocardial pattern.28 Valve morphology and atrial size are also reviewed. These findings help guide treatment decisions and monitoring.

Functional assessment examines how effectively the ventricles pump and relax. Systolic function is measured by the ejection fraction and fractional shortening, which are accessible estimates of pumping strength.29,30 Diastolic function, or how well the ventricles relax to allow blood filling, is evaluated using Doppler inflow patterns and tissue Doppler velocities.31 The myocardial performance index (MPI) integrates systolic and diastolic intervals and is useful in paediatrics and research, though less reproducible and not part of routine daily practice.32,33 Strain imaging can detect subtle impairment before traditional indices decline.34,35

Flow assessment uses Doppler to evaluate blood movement across valves and outflow tracts. It identifies left ventricular outflow obstruction in hypertrophic cardiomyopathy, quantifies regurgitation, and detects abnormal shunts.36 Right ventricular performance is commonly measured using tricuspid annular plane systolic excursion (TAPSE), fractional area change, or RV strain.37,38 Doppler also estimates pulmonary pressures, which are frequently elevated in advanced cardiomyopathy.39 These assessments explain symptoms such as breathlessness or fatigue and highlight treatment needs.

Deformation (strain) imaging provides a more detailed view of myocardial mechanics. Speckle-tracking strain quantifies subtle muscle shortening and lengthening, while newer indices such as myocardial work integrate strain with blood pressure to estimate ventricular efficiency.40,41 These methods are promising in children, and ongoing studies will clarify how best to integrate them into routine practice.

Together, structural, functional, flow, and deformation measures provide the foundation for diagnosing pediatric cardiomyopathy, tracking progression, and tailoring family-centred care.

Clinical applications

Echocardiography is the first-line tool for assessing pediatric cardiomyopathy. It provides crucial structural and functional insights, though complementary investigations such as cardiac MRI, ECG, Holter monitoring, exercise testing, and genetic studies are often required to give a complete picture.42, 43

Diagnosis

Echocardiography helps differentiate dilated, hypertrophic, restrictive, and noncompaction cardiomyopathies by assessing chamber size, wall thickness, and pump function. This makes it central to early recognition, although cardiac MRI is often used when more detailed tissue characterisation or clearer imaging is needed.44,45

Monitoring

In follow-up care, serial echocardiograms are widely used to track ventricular function, valve regurgitation, and pulmonary pressures 46, 47. These findings guide treatment adjustments and help determine when to consider advanced interventions. Follow-up is often every 6–12 months, though intervals can be shorter in unstable patients or longer in stable, asymptomatic relatives, depending on risk and clinical stability 48, 49.

Risk assessment

Findings such as progressive dilation, severe hypertrophy, or impaired filling can contribute to identifying children at higher risk of heart failure or sudden cardiac events.11 However, echocardiography alone is insufficient; risk assessment should be integrated with clinical features, ECG, MRI, and sometimes exercise or Holter data.11,50 ICDs are considered only in selected high-risk children, given the risks of complications, and decisions are always based on multiple risk markers rather than echocardiography alone.11,50

Family screening

Because many cardiomyopathies are inherited, echocardiography is also used in screening first-degree relatives.51, 52 Screening protocols are usually tailored to age, genetic background, and clinical findings, and may include genetic testing alongside imaging. This proactive approach helps detect early changes and guides family counselling.51, 53

Strengths and limitations

Echocardiography remains the first-line modality for evaluating pediatric cardiomyopathy because it is safe, non-invasive, and radiation-free. It is also widely available and less costly than MRI or CT, which makes it practical for repeated monitoring.42 Crucially, it provides real-time information on cardiac structure, function, blood flow, and hemodynamics such as pressure gradients and diastolic performance, guiding both diagnosis and follow-up.

However, there are important limitations. Image quality can be reduced in children with obesity, complex anatomy, or fast heart rates, and results remain operator dependent, although standardised protocols and newer automation can mitigate but not eliminate this variability.54 Even with advances like strain and 3D imaging, echocardiography does not reliably detect diffuse fibrosis or infiltrative myocardial changes, areas where MRI provides clearer tissue characterisation.55,56 Still, MRI itself has drawbacks, including higher cost, longer exam times, limited access, and the need for sedation in younger children.55

Thus, echocardiography is best regarded as a foundational tool in pediatric cardiomyopathy, complemented by MRI when more detailed tissue assessment is required.

Future directions

Looking ahead, several new techniques may enhance how doctors use echocardiography for children with cardiomyopathy. Though results can vary between systems, strain imaging is already used in many centres. It measures tiny changes in heart muscle movement to spot subtle dysfunction, sometimes before standard measures like ejection fraction change.57, 58 Three-dimensional echocardiography gives a fuller picture of the heart’s shape and brings measurements closer to those seen with MRI, though MRI remains the gold standard, particularly in complex cases.22,59 Contrast echocardiography can improve image clarity and, in selected research settings, assess blood flow in the heart muscle, but it remains uncommon in pediatric clinical practice.60, 61 Finally, early-stage artificial intelligence tools may help standardise scan quality and interpretation, aiming ultimately to improve care.62,63

Conclusion

Echocardiography remains the cornerstone in assessing pediatric cardiomyopathy, valued for being safe, non-invasive, and able to provide real-time insights into cardiac structure, function, and blood flow.64,65 Its role extends beyond initial diagnosis to long-term monitoring, guiding therapy, and supporting family screening.11,66 However, echocardiography alone is not always sufficient for risk prediction, particularly in conditions where arrhythmias or sudden death are concerns, and complementary tools such as MRI, ECG, Holter monitoring, or genetic testing are often needed.67,68,69 In most cases, echocardiography is the essential first-line modality, though MRI may be preferable when image quality is limited.42 Looking forward, advances such as strain imaging, 3D echocardiography, and artificial intelligence are enhancing accuracy, though reproducibility and standardisation remain challenges in pediatrics.23,70,71 Combined with innovation, echocardiography remains central to improving outcomes and quality of life for affected children.

References

  1. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. The New England journal of medicine [Internet]. 2003;348(17):1647–55. Available from: https://www.ncbi.nlm.nih.gov/pubmed/12711739
  2. Lee TM, Hsu DT, Kantor P, Towbin JA, Ware SM, Colan SD, et al. Pediatric Cardiomyopathies. Circulation Research. 2017 Sep 15;121(7):855–73.
  3. Wilkinson JD, Landy DC, Colan SD, Towbin JA, Sleeper LA, Orav EJ, et al. The Pediatric Cardiomyopathy Registry and Heart Failure: Key Results from the First 15 Years. Heart failure clinics [Internet]. 2010 Oct 1 [cited 2021 Mar 24];6(4):401–13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2946942/
  4. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden Deaths in Young Competitive Athletes. Circulation. 2009 Mar 3;119(8):1085–92.
  5. Towbin JA, McKenna WJ, Abrams DJ, Ackerman MJ, Calkins H, Darrieux FCC, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm [Internet]. 2019 Nov [cited 2019 Nov 8];16(11):e301–72. Available from: https://www.sciencedirect.com/science/article/pii/S1547527119304382
  6. Malinow I, Fong DC, Miyamoto M, Badran S, Hong CC. Pediatric dilated cardiomyopathy: a review of current clinical approaches and pathogenesis. Frontiers in Pediatrics [Internet]. 2024 Jun 19;12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11223501/
  7. Kindel SJ, Miller EM, Gupta R, Cripe LH, Hinton RB, Spicer RL, et al. Pediatric Cardiomyopathy: Importance of Genetic and Metabolic Evaluation. Journal of Cardiac Failure. 2012 May;18(5):396–403.
  8. Bharucha T, Lee KJ, Daubeney PEF, Nugent AW, Turner C, Sholler GF, et al. Sudden Death in Childhood Cardiomyopathy. Journal of the American College of Cardiology. 2015 Jun;65(21):2302–10.
  9. Webber SA, Lipshultz SE, Sleeper LA, Lu M, Wilkinson JD, Addonizio LJ, et al. Outcomes of Restrictive Cardiomyopathy in Childhood and the Influence of Phenotype. Circulation. 2012 Sep 4;126(10):1237–44.
  10. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. Circulation [Internet]. 2016 Dec 6;134(23). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000455
  11. Lipshultz SE, Cochran TR, Briston DA, Brown SR, Sambatakos PJ, Miller TL, et al. Pediatric cardiomyopathies: causes, epidemiology, clinical course, preventive strategies and therapies. Future Cardiology. 2013 Nov;9(6):817–48.
  12. Adalena Tsatsopoulou, Ioannis Protonotarios, Zafeirenia Xylouri, Ioannis Papagiannis, Aris Anastasakis, Ioannis Germanakis, et al. Cardiomyopathies in children: An overview. Hellenic Journal of Cardiology. 2023 Jul 1;72:43–56.
  13. Dai Y, Wang Y, Fan Y, Han B. Genotype-phenotype insights of pediatric dilated cardiomyopathy. Frontiers in Pediatrics. 2025 Jan 31;13.
  14. Basit H, Brito D, Sharma S. Hypertrophic Cardiomyopathy [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430788/
  15. Marian AJ, Braunwald E. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research. 2017 Sep 15;121(7):749–70.
  16. Restrictive cardiomyopathy: A review of literature on clinical status and meta-analysis of diagnosis and clinical management methods table of contents [Internet]. Oatext.com. 2015. Available from: https://www.oatext.com/restrictive-cardiomyopathy-a-review-of-literature-on-clinical-status-and-meta-analysis-of-diagnosis-and-clinical-management-methods-table-of-contents.php
  17. Singh DP, Patel H. Left Ventricular Non-compaction Cardiomyopathy [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537025/
  18. Hershberger RE, Cowan J, Jordan E, Kinnamon DD. The Complex and Diverse Genetic Architecture of Dilated Cardiomyopathy. Circulation Research. 2021 May 14;128(10):1514–32.
  19. Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, et al. Incidence, Causes, and Outcomes of Dilated Cardiomyopathy in Children. JAMA [Internet]. 2006 Oct 18;296(15):1867. Available from: https://jamanetwork.com/journals/jama/fullarticle/203681
  20. Grant MD, Mann RD, Kristenson SD, Buck RM, Mendoza JD, Reese JM, et al. Transthoracic Echocardiography: Beginner’s Guide with Emphasis on Blind Spots as Identified with CT and MRI. RadioGraphics [Internet]. 2021 Jun 11;41(4):200142. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8493765/
  21. Tsai SK. The role of transesophageal echocardiography in clinical use. Journal of the Chinese Medical Association. 2013 Dec;76(12):661–72.
  22. Lang RM, Mor-Avi V, Sugeng L, Nieman PS, Sahn DJ. Three-Dimensional Echocardiography. Journal of the American College of Cardiology [Internet]. 2006 Nov;48(10):2053–69. Available from: https://www.sciencedirect.com/science/article/pii/S0735109706021085
  23. Baessato F, Romeo C, Rabbat MG, Pontone G, Meierhofer C. A Comprehensive Assessment of Cardiomyopathies through Cardiovascular Magnetic Resonance: Focus on the Pediatric Population. Diagnostics [Internet]. 2022 May 1 [cited 2022 Nov 1];12(5):1022. Available from: https://www.mdpi.com/2075-4418/12/5/1022
  24. Chaudhari M, Mahi Lakshmi Ashwath. Cardiac Imaging in the Diagnosis and Management of Heart Failure. Journal of Clinical Medicine [Internet]. 2025 Jul 15;14(14):5002–2. Available from: https://www.mdpi.com/2077-0383/14/14/5002
  25. Teja Senekovič Kojc, Varda NM. Echocardiographic Strain Imaging in Pediatrics. IntechOpen eBooks [Internet]. 2025 Aug 4 [cited 2025 Sep 28]; Available from: https://www.intechopen.com/online-first/1210535
  26. Mathew T, Williams L, Navaratnam G, Rana B, Wheeler R, Collins K, et al. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography. Echo Research and Practice. 2017 Jun;4(2):G1–13.
  27. Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Circulation. 2020 Dec 22;142(25).
  28. FLORIA M, Grigore TINICA, GRECU M. Left Ventricular Non-Compaction –Challenges and Controversies. Mædica [Internet]. 2014 Sep [cited 2025 Sep 28];9(3):282. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC4306000/
  29. Chengode S. Left Ventricular Global Systolic Function Assessment by Echocardiography. Annals of Cardiac Anaesthesia [Internet]. 2016;19(5):26. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5100240/
  30. Kosaraju A, Makaryus AN. Left Ventricular Ejection Fraction [Internet]. National Library of Medicine. StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459131/
  31. Mottram PM. Assessment of diastolic function: what the general cardiologist needs to know. Heart. 2005 May 1;91(5):681–95.
  32. Jerbi AE, Erdem S, Gaitonde M, Gusseva M, Greil G, Zou Q, et al. The Feasibility and Reproducibility of Measuring Myocardial Performance Index Using Two-Dimensional Phase Contrast Imaging in Patients with Congenital Heart Disease. Pediatric Cardiology. 2025 Jul 16;
  33. Dyer KL, Pauliks LB, Das B, Shandas R, Ivy D, Shaffer EM, et al. Use of Myocardial Performance Index in Pediatric Patients with Idiopathic Pulmonary Arterial Hypertension. Journal of the American Society of Echocardiography [Internet]. 2006 Jan [cited 2025 Sep 28];19(1):21–7. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC1934985/
  34. Brady B, King G, Murphy RT, Walsh D. Myocardial strain: a clinical review. Irish Journal of Medical Science (1971 -). 2022 Nov 16;
  35. Mihos CG, Liu JE, Anderson KM, Pernetz MA, O’Driscoll JM, Aurigemma GP, et al. Speckle-Tracking Strain Echocardiography for the Assessment of Left Ventricular Structure and Function: A Scientific Statement From the American Heart Association. Circulation. 2025 Aug 6;
  36. Vilcant V, Hai O. Left Ventricular Outflow Tract Obstruction [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470446/
  37. Lee JZ, Low SW, Pasha AK, Howe CL, Lee KS, Suryanarayana PG. Comparison of tricuspid annular plane systolic excursion with fractional area change for the evaluation of right ventricular systolic function: a meta-analysis. Open Heart. 2018 Jan;5(1):e000667.
  38. Bleeker GB, Steendijk P, Holman ER, Yu C, Breithardt OA, Kaandorp TAM, et al. Assessing right ventricular function: the role of echocardiography and complementary technologies. Heart [Internet]. 2006 Apr 1;92(Suppl 1):i19–26. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1860734/
  39. Tsujimoto Y, Junji Kumasawa, Shimizu S, Nakano Y, Kataoka Y, Tsujimoto H, et al. Doppler trans-thoracic echocardiography for detection of pulmonary hypertension in adults. Cochrane library. 2022 May 9;2022(5).
  40. Smiseth OA, Rider O, Cvijic M, Ladislav Valkovič, Remme EW, Voigt JU. Myocardial Strain Imaging. JACC Cardiovascular imaging. 2024 Sep 1;18(3).
  41. Smiseth OA, Torp H, Opdahl A, Haugaa KH, Urheim S. Myocardial strain imaging: how useful is it in clinical decision making? European Heart Journal. 2015 Oct 27;37(15):1196–207.
  42. Moscatelli S, Leo I, Bianco F, Borrelli N, Beltrami M, Garofalo M, et al. The Role of Multimodality Imaging in Pediatric Cardiomyopathies. Journal of Clinical Medicine [Internet]. 2023 Jul 24 [cited 2025 Sep 28];12(14):4866. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10381492/
  43. Ntsinjana HN, Hughes ML, Taylor AM. The Role of Cardiovascular Magnetic Resonance in Pediatric Congenital Heart Disease. Journal of Cardiovascular Magnetic Resonance. 2011 Sep 21;13(1).
  44. Pinamonti B, Abate E, De Luca A, Finocchiaro G, Korcova R. Role of Cardiac Imaging: Echocardiography [Internet]. Sinagra G, Merlo M, Pinamonti B, editors. PubMed. Cham (CH): Springer; 2019. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553855/
  45. Pender A, Lewis-Owona J, Ekiyoyo A, Stoddard M. Echocardiography and Heart Failure: An Echocardiographic Decision Aid for the Diagnosis and Management of Cardiomyopathies. Current cardiology reports [Internet]. 2025;27(1):64. Available from: https://pubmed.ncbi.nlm.nih.gov/40019673/
  46. Augustine DX, Coates-Bradshaw LD, Willis J, Harkness A, Ring L, Grapsa J, et al. Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. Echo research and practice [Internet]. 2018;5(3):G11–24. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30012832
  47. Price S, Platz E, Cullen L, Tavazzi G, Christ M, Cowie MR, et al. Echocardiography and lung ultrasonography for the assessment and management of acute heart failure. Nature Reviews Cardiology. 2017 Apr 27;14(7):427–40.
  48. Saji AM, Sharma S. Pulmonary Regurgitation [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557564/
  49. Mah K, Mertens L. Echocardiographic Assessment of Right Ventricular Function in Pediatric Heart Disease: A Practical Clinical Approach. CJC Pediatric and Congenital Heart Disease. 2022 May;
  50. Ditaranto R, Caponetti AG, Ferrara V, Parisi V, Minnucci M, Chiti C, et al. Pediatric Restrictive Cardiomyopathies. Frontiers in Pediatrics. 2022 Jan 25;9.
  51. Kim KH, Pereira NL. Genetics of Cardiomyopathy: Clinical and Mechanistic Implications for Heart Failure. Korean Circulation Journal. 2021;51(10).
  52. Jacoby D, McKenna WJ. Genetics of inherited cardiomyopathy. European Heart Journal [Internet]. 2011 Aug 2;33(3):296–304. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3270042/
  53. Ylipää J, Andersson T. Genetic analysis and family screening for dilated cardiomyopathy: a retrospective analysis of the stepwise pedigree approach. Scandinavian Cardiovascular Journal. 2024 Jul 24;58(1).
  54. Nimpum D, Jittham W. Echocardiographic assessment of cardiac function abnormalities and related risk factors in Thai overweight and obese children. Annals of Pediatric Cardiology. 2023 Nov;16(6):413–21.
  55. Hassan S, Barrett CJ, Crossman DJ. Imaging tools for assessment of myocardial fibrosis in humans: the need for greater detail. Biophysical Reviews [Internet]. 2020 Jul 23 [cited 2025 Sep 28];12(4):969–87. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC7429810/
  56. Zhu L, Wang Y, Zhao S, Lu M. Detection of myocardial fibrosis: Where we stand. Frontiers in Cardiovascular Medicine [Internet]. 2022 Sep 29 [cited 2023 Sep 8];9:926378. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557071/#:~:text=Myocardial%20fibrosis%2C%20resulting%20from%20the
  57. Lopez-Candales A, Hernandez-Suarez DF. Strain Imaging Echocardiography: What Imaging Cardiologists Should Know. Current Cardiology Reviews [Internet]. 2017 Mar 1;13(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452148/
  58. Iskander J, Kelada P, Rashad L, Massoud D, Afdal P, Abdelmassih AF. Advanced Echocardiography Techniques: The Future Stethoscope of Systemic Diseases. Current Problems in Cardiology. 2022 Jun;47(6):100847.
  59. Barbieri A, Pepi M. Three-Dimensional Echocardiography Based on Automation and Machine Learning Principles and the Renaissance of Cardiac Morphometry. Journal of Clinical Medicine [Internet]. 2022 Jul 27 [cited 2025 Sep 28];11(15):4357–7. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9369091/
  60. Hampson R, Senior R, Ring L, Robinson S, Augustine D, Becher H, et al. Contrast echocardiography: a practical guideline from the British Society of Echocardiography. Echo Research & Practice. 2023 Nov 15;10(1).
  61. Eskandari M, Monaghan M. Contrast echocardiography in daily clinical practice. Herz. 2017 Feb 3;42(3):271–8.
  62. Nguyen M, Olivier Villemain, Friedberg MK, Lasse Løvstakken, Rusin CG, Mertens L. Artificial intelligence in the pediatric echocardiography laboratory: Automation, physiology, and outcomes. Frontiers in radiology. 2022 Sep 9;2.
  63. Jiang L, Zuo HJ, Chen C. Artificial intelligence in echocardiography: Applications and future directions. Fundamental Research. 2025 Apr;
  64. Mandeş L, Roşca M, Ciupercă D, Popescu BA. The role of echocardiography for diagnosis and prognostic stratification in hypertrophic cardiomyopathy. Journal of Echocardiography. 2020 Apr 16;18(3):137–48.
  65. Beer M, B Schönnagel, Herrmann J, Steffen Klömpken, Schaal M, Kaestner M, et al. Non-invasive pediatric cardiac imaging—current status and further perspectives. Molecular and Cellular Pediatrics. 2022 Dec 28;9(1).
  66. Trasca L, Popescu MR, Popescu AC, Balanescu SM. Echocardiography in the Diagnosis of Cardiomyopathies: Current Status and Future Directions. Reviews in Cardiovascular Medicine. 2022 Aug 10;23(8):280.
  67. Moisa SM, Spoiala EL, Cinteza E, Radu Vatasescu, Lacramioara Ionela Butnariu, Brinza C, et al. Arrhythmogenic Right Ventricular Cardiomyopathy in Children: A Systematic Review. Diagnostics [Internet]. 2024 Jan 12;14(2):175–5. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10814764/
  68. Marco Valerio Mariani, Pierucci N, Fanisio F, Laviola D, Silvetti G, Piro A, et al. Inherited Arrhythmias in the Pediatric Population: An Updated Overview. Medicina. 2024 Jan 3;60(1):94–4.
  69. te Riele ASJM, James CA, Calkins H, Tsatsopoulou A. Arrhythmogenic Right Ventricular Cardiomyopathy in Pediatric Patients: An Important but Underrecognized Clinical Entity. Frontiers in Pediatrics. 2021 Dec 2;9.
  70. Johnson CL, Upton R, Krasner S, Bennett S, Ackerman A, Liu X, et al. Clinical research and trials in echocardiography: rationale, requirements and future opportunities. Echo Research and Practice. 2025 Aug 10;12(1).
  71. Maturi B, Dulal S, Sayana SB, Ibrahim A, Ramakrishna M, Chinta V, et al. Revolutionizing Cardiology: The Role of Artificial Intelligence in Echocardiography. Journal of Clinical Medicine. 2025 Jan 19;14(2):625.
Share

Ramya Nadig

Master of Science - MS, Biomedical and Molecular Sciences, University of Dundee

Ramya is a biomedical science graduate who is interested in helping people understand health information more clearly. She studied biotechnology and later completed a master’s degree in biomedical and molecular sciences, which introduced her to how illnesses are researched and how medical knowledge is built. Through various research and community projects, she became more aware of how easily scientific language can feel confusing or inaccessible. This led her to focus on science communication and patient-friendly writing. At Klarity, she aims to present medical information in a clear, steady, and supportive way so readers can feel more informed about their health. She values accuracy, clarity, and empathy, and hopes her writing is helpful to those looking for straightforward explanations.

arrow-right